160 related articles for article (PubMed ID: 22138483)
1. E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.
Fourati S; Malet I; Guenzel CA; Soulie C; Maidou-Peindara P; Morand-Joubert L; Wirden M; Sayon S; Peytavin G; Simon A; Katlama C; Benichou S; Calvez V; Marcelin AG
Antiviral Res; 2012 Jan; 93(1):167-74. PubMed ID: 22138483
[TBL] [Abstract][Full Text] [Related]
2. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
3. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
4. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
5. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Miranda LR; Götte M; Liang F; Kuritzkes DR
Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
[TBL] [Abstract][Full Text] [Related]
6. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
[TBL] [Abstract][Full Text] [Related]
7. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
[TBL] [Abstract][Full Text] [Related]
8. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
9. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
[TBL] [Abstract][Full Text] [Related]
10. An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.
Capdepont S; Aurillac-Lavignolle V; Faure M; Dupon M; Morlat P; Ragnaud JM; Chêne G; Fleury H; Masquelier B;
J Clin Virol; 2006 May; 36(1):36-42. PubMed ID: 16513416
[TBL] [Abstract][Full Text] [Related]
11. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
12. Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.
Svedhem V; Lindkvist A; Lidman K; Sönnerborg A
J Med Virol; 2002 Dec; 68(4):473-8. PubMed ID: 12376953
[TBL] [Abstract][Full Text] [Related]
13. Clinically relevant genotype interpretation of resistance to didanosine.
Marcelin AG; Flandre P; Pavie J; Schmidely N; Wirden M; Lada O; Chiche D; Molina JM; Calvez V;
Antimicrob Agents Chemother; 2005 May; 49(5):1739-44. PubMed ID: 15855490
[TBL] [Abstract][Full Text] [Related]
14. Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.
Vidal C; Arnedo M; Garcia F; Mestre G; Plana M; Cruceta A; Capon A; Gallart T; Miro JM; Pumarola T; Gatell JM
Antivir Ther; 2002 Dec; 7(4):283-7. PubMed ID: 12553483
[TBL] [Abstract][Full Text] [Related]
15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
16. Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons.
García-Lerma JG
J Antimicrob Chemother; 2005 Aug; 56(2):265-9. PubMed ID: 15951354
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
McColl DJ; Chappey C; Parkin NT; Miller MD
Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.
Flandre P; Marcelin AG; Pavie J; Shmidely N; Wirden M; Lada O; Bernard MC; Molina JM; Calvez V
Antivir Ther; 2005; 10(4):479-87. PubMed ID: 16038473
[TBL] [Abstract][Full Text] [Related]
19. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
Betancor G; Nevot M; Mendieta J; Gómez-Puertas P; Martínez MA; Menéndez-Arias L
Antiviral Res; 2014 Jun; 106():42-52. PubMed ID: 24667336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]